Novonesis

Overview

Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen, creating the world's largest microbial and enzyme solutions company. The combined company engineers and produces a vast portfolio of industrial enzymes, microbial cultures, specialty fermentation ingredients, and biostimulants used in food production, agriculture, animal health, cleaning products, biofuels, and pharmaceutical manufacturing. Novonesis products are estimated to be present in approximately 50% of the world's grain ethanol, 40% of global bread production, and a significant share of laundry detergents, cheese, and probiotic supplements. Customers across food & beverage, biofuels, agriculture, animal nutrition, and industrial cleaning use Novonesis enzyme and microbial solutions to improve yields, reduce energy consumption, replace petrochemical inputs, and enhance sustainability metrics. In pharmaceutical manufacturing, Novonesis supplies enzyme packages for active pharmaceutical ingredient synthesis, enabling greener chemistry processes. In agriculture, its microbial products (including BioAg partnerships) provide plant growth promotion, nitrogen fixation, and disease suppression. Novonesis's differentiation lies in its unmatched scale of biological discovery and optimization infrastructure accumulated over more than 80 years of combined operations. The company has identified and engineered enzymes from thousands of microbial sources, maintains some of the world's deepest patent estates in industrial enzymology, and operates manufacturing fermentation capacity at a scale that enables cost parity with synthetic chemical alternatives. The merger with Chr. Hansen adds proprietary cultures, probiotics, and fermentation expertise that extends Novonesis's biosolutions into human and animal health.

Key Features

Pros & Cons

Use Cases